Aman, J, Duijvelaar, E, Botros, L, Kianzad, A
, Schippers, J, Smeele, P, Azhang, S
, Bartelink, I, Bet, P, Boersma, W, Boomars, K, Bonta, P
, Bos, L, Van Bragt, J, Braunstahl, G-J
, Celant, L, Eger, K, Geelhoed, M, Van Glabbeek, Y, Grotjohan, H, Hagens, L
, Happe, C, Heunks, L, Van Den Heuvel, M, Hoefsloot, W, Hoek, R, Hoekstra, R, Hofstee, H, Vanhove, A, Juffermans, N, Lammers, M, Kos, R, Kemper, M, Kunst, P, Van Der Lee, I, Van Der Lee, L, Mau-Asam, P, Maitland-Van Der Zee, A-H
, Mieras, A, Nossent, E, Overbeek, M, Oswald, L, Paternotte, N, Pamplona, C, Pronk, N, De Raaf, M, Slob, E, Neto, AS, Schultz, M, Smit, M, Smeenk, F
, Smits, J, Stalenhoef, J
, Tuinman, PR, Wessels, J, Van Wezenbeek, J
, Noordegraaf, AV, Handoko-De Man, F & Bogaard, HJ 2021, '
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19',
European respiratory journal, vol. 58.
https://doi.org/10.1183/13993003.congress-2021.OA4119